- Home
- WFCF vs BMEA Comparison
WFCF vs BMEA Comparison
Compare WFCF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFCF
- BMEA
- Stock Information
- Founded
- WFCF 1996
- BMEA 2017
- Country
- WFCF United States
- BMEA United States
- Employees
- WFCF N/A
- BMEA N/A
- Industry
- WFCF Computer Software: Prepackaged Software
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- WFCF Technology
- BMEA Health Care
- Exchange
- WFCF Nasdaq
- BMEA Nasdaq
- Market Cap
- WFCF 59.0M
- BMEA 65.8M
- IPO Year
- WFCF 2011
- BMEA 2021
- Fundamental
- Price
- WFCF $11.16
- BMEA $1.63
- Analyst Decision
- WFCF
- BMEA Strong Buy
- Analyst Count
- WFCF 0
- BMEA 10
- Target Price
- WFCF N/A
- BMEA $17.90
- AVG Volume (30 Days)
- WFCF 2.5K
- BMEA 796.1K
- Earning Date
- WFCF 08-07-2025
- BMEA 08-05-2025
- Dividend Yield
- WFCF N/A
- BMEA N/A
- EPS Growth
- WFCF N/A
- BMEA N/A
- EPS
- WFCF 0.39
- BMEA N/A
- Revenue
- WFCF $25,604,000.00
- BMEA N/A
- Revenue This Year
- WFCF N/A
- BMEA N/A
- Revenue Next Year
- WFCF N/A
- BMEA N/A
- P/E Ratio
- WFCF $29.96
- BMEA N/A
- Revenue Growth
- WFCF N/A
- BMEA N/A
- 52 Week Low
- WFCF $8.76
- BMEA $1.29
- 52 Week High
- WFCF $51.15
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- WFCF 50.73
- BMEA 41.97
- Support Level
- WFCF $11.15
- BMEA $1.50
- Resistance Level
- WFCF $11.27
- BMEA $1.65
- Average True Range (ATR)
- WFCF 0.12
- BMEA 0.10
- MACD
- WFCF -0.03
- BMEA -0.01
- Stochastic Oscillator
- WFCF 33.33
- BMEA 32.50
About WFCF Where Food Comes From Inc.
Where Food Comes From Inc is a third-party food verification company. It offers food production audits and uses verification processes to ensure that claims made by food producers and processors are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. The company operates in two segments that are verification and certification and Software Sales and Related Consulting. It generates the majority of its revenue from verification and certification.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.